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Abstract
Background: Several inflammatory cytokines play a key part in the induction of osteoporosis. Until now, involvement
of the Th2 cytokine interleukin-31 (IL-31) in osteoporosis hadn’t yet been studied. IL-31 is a proinflammatory cytokine
mediating multiple immune functions, whose involvement in a wide range of diseases, such as atopic dermatitis,
inflammatory bowel diseases and cutaneous lymphomas, is now emerging. Given the important role of IL-31 in
inflammation, we measured its serum levels in postmenopausal osteoporotic patients.
Methods and results: In fifty-six postmenopausal females with osteoporosis and 26 healthy controls, bone mineral
density (BMD) measurements were performed by using calcaneal quantitative ultrasound (QUS) technique, confirmed
at the lumbar spine and hip by dual energy X-ray absorptiometry (DXA). Both patients and controls were divided
according to age (less or more than 65 years) and disease severity (T-score levels and presence of fractures).
Serum IL-31 levels were measured by ELISA technique. Osteoporotic patients exhibited elevated levels of serum
IL-31 compared with healthy controls (43.12 ± 6.97 vs 29.58 ± 6.09 pg/ml; p < 0.049). IL-31 expression was higher
in over 65 years old patients compared to age-matched controls (45 ± 11.05 vs. 17.92 ± 5.92; p < 0.01), whereas in
younger subjects no statistically significant differences were detected between patients and controls (37.91 ± 6.9
vs 32.08 ± 8.2). No statistically significant differences were found between IL-31 levels in patients affected by mild
(T-score > -3) compared to severe (T-score < -3) osteoporosis (59.17 ± 9.22 vs 37.91 ± 10.52), neither between
fractured and unfractured osteoporotic women (33.75 ± 9.16 vs 51.25 ± 8.9).
Conclusions: We showed for the first time an increase of IL-31 serum levels in postmenopausal women with
decreased BMD. Although they did not reflect the severity of osteoporosis and/or the presence of fractures, they
clearly correlated with age, as reflected by the higher levels of this cytokine in aged patients.
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Background
In the last few years, many studies have been conducted
to understand the processes that regulate physiological
and pathological bone turnover and there was increasing
evidence of a relationship between the immune system
and bone [1, 2]. There is a mutual influence between
the immune system and bone tissue cells, mediated by
shared receptors, soluble molecules and signalling path-
ways [3]. T cells have been recognized as key regulators
of osteoclast and osteoblast activity in different diseases
able to induce osteoporosis, such as rheumatic diseases,
bone metastasis, periodontitis and chronic infections
[4–6]. Also paraphysiological conditions, such as aging
and menopause, are associated to dysregulation of bone
remodelling leading to loss of bone mass and conse-
quentely, to a state of full-blown osteoporosis [7–9].
Osteoporosis is a systemic skeletal disease character-
ized by decreased bone mass and microarchitectural de-
terioration of bone tissue. An excessive bone resorption
and/or an inadequate bone formation results in a subse-
quent increase in bone fragility and susceptibility to
fractures [10]. The main regulator of osteoclast differ-
entiation is the receptor activator of nuclear factor-kB
(NF-kB) ligand (RANKL), a factor produced by osteo-
blasts/stromal cells and belonging to the tumour necro-
sis factor (TNF) family. In the presence of the growth
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factor M-CSF (macrophage-colony stimulating factor),
the activation of its receptor RANK on the surface of
osteoclast precursors and mature osteoclasts represents
an essential signal for osteoclast differentiation and ac-
tivation and consequentely bone resorption [11]. Inter-
estingly, immune cells, mainly activated T lymphocytes
and antigen presenting cells, can also express RANKL,
therefore influencing bone remodelling, both directely
and through cytokine production [12]. For example, IL-
6, IL-17, TNF-α and IFN-γ promote bone loss by
favouring osteoclast production and inhibiting osteo-
blast differentiation [13, 14]. Other cytokines, such as
IL-4, IL-12 and IL-33, are strong suppressors of osteo-
clast differentiation and inhibit bone loss [15, 16]. In
addition, many of these cytokines have pleiotropic func-
tions and their role in bone remodelling is cell-type and
concentration-dependent and also influenced by the
variable cytokine network involved in different physio-
logical and pathological conditions [3].
Interleukin-31 (IL-31) is a cytokine known for almost
a decade, belonging to the gp130/IL-6 cytokine family
[17] and preferentially expressed by activated memory
CD45RO+ T lymphocytes skewed toward a Th2 pheno-
type [18–22]. Elucidation of the biological activities of
IL-31 has only just begun and a biological role of IL-31
in immunity and inflammation is now emerging [18, 19].
It has been observed that this cytokine plays a predom-
inant function in the mediation of inflammatory and
lymphoma-associated itch [23], and a secondary one in
the suppression of ongoing TH2 responses [17]. IL-31
signals through a heteromeric receptor complex com-
posed of the IL-31 receptor alpha (IL-31RA) and the
oncostatin M receptor beta (OSMR) subunits [20].
High receptor expression levels have been found in tis-
sues involved in reproduction, in progenitor cells of
myelomonocytic lineage, spleen, thymus, in addition to
skin, lung, gut and other tissues [17, 20, 23, 24]. IL-
31RA is also expressed by a small subpopulation of
neurons, representing a critical neuro-immune link be-
tween Th2 cells and sensory nerves for the generation
of immune-mediated itch [25]. The broad spectrum of
its receptor expression on immune- and non-immune
cells, suggests that this novel cytokine may have mul-
tiple, pleiotropic physiological functions, including
regulating hematopoiesis and immune response, caus-
ing inflammation [17, 21].
IL-31 stimulates secretion of proinflammatory cyto-
kines, chemokines, and matrix metalloproteinases [17, 26].
Moreover, it has been observed that IL-31 can positively
and negatively affect Th1 and Th17 differentiation in an
APC-free system [17]. These data suggest a potential func-
tion for IL-31 in regulating immune responses through
modulating antigen-presenting cells or more directly T cell
themselves. Earlier studies have shown involvement of IL-
31 and its receptor components IL-31RA and OSMR in
atopic dermatitis, pruritus and Th2-weighted inflamma-
tion [20, 27]. Until today it has been implicated in cutane-
ous pathologies [18, 20, 23, 28], inflammatory bowel
diseases [29], atopy [18, 23, 27, 28, 30, 31], respiratory in-
flammation [32] and some types of tumours [33, 34], but
its role in osteoporosis hadn’t yet been studied. The
aim of our study was to evaluate the possible involve-
ment of IL-31 also in subjects affected by osteoporosis.
Methods
Patients
Fifty-six post-menopausal females with osteoporosis
(mean age ± standard deviation: 65.39 ± 9.68 years) and
26 age-matched (61.84 ± 8.03 years) healthy post-
menopausal women as controls, were enrolled in this
study after written informed consent. The study was ap-
proved by the local ethics committee and carried out in
compliance with the Helsinky Declaration [35]. In all
subjects, bone mineral density (BMD) measurements
were performed by using computerized methods: calca-
neal quantitative ultrasound (QUS) technique (Lunar
Achilles Express densitometer), confirmed at the lumbar
spine and hip by dual energy X-ray absorptiometry
(DXA) (Hologic QDR 4500 W machine). BMD values
obtained by DXA technique were expressed as T-score,
i.e. the difference (number of standard deviations) be-
tween the BMD value of the examined subject and the
mean value in the healthy reference population. Z-score
(the patient’s BMD compared with the mean BMD of
people of the same sex and age) and BMD values
expressed as g/cm2, were also collected and they are
shown in Table 1.
T-score values between +1 and -1 were considered
normal, whereas T-score below -2.5 defined osteoporosis.
Collected data also included careful medical history, accur-
ate clinical examination, assessment of anthropometric pa-
rameters (height, weight and body mass index) and
laboratory and instrumental tests, such as spinal X-ray and
vertebral morphometry to check for any asymptomatic
osteoporotic fractures. Among laboratory tests, we included
inflammation markers, such as erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP), as well as parathy-
roid hormone (PTH) values and serum markers of bone
remodeling, such as bone alkaline phosphatase (BAP) and
C-telopeptide cross-linked collagen type 1 (CTX).
None of the studied subjects had pathologies causing
secondary osteoporosis, or took drugs that could affect
bone metabolism [6]. Diagnosis was made according to
the current criteria of the World Health Organization
[10], which is based on the T-score for the classification of
the BMD into categories of normal, osteopenia, osteopor-
osis, and severe osteoporosis. Thus patients were further
divided, according to the BMD value, into two groups: 27
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patients with T-score > -3 (mean age 64.59 ± 9.24 years)
and 29 with T-score < -3 (mean age 66.13 ± 10.18 years).
The definition of mild or severe osteoporosis is related to
hip BMD values obtained from DXA. Both patients and
controls were also divided according to age: less than or
equal to 65 years (n. 43; mean age 56.91 ± 6.03 years) and
older than 65 years (n. 39; mean age 72.38 ± 3.89 years).
Serum IL-31 levels were measured in both patients and
controls. Blood samples were obtained by venipuncture
and centrifuged at 3000 rpm for 5 min. Serum samples
were stored at -20 °C until use.
IL-31 dosage
IL-31 protein levels were evaluated using a standard sand-
wich ELISA kit according to the manufacturer’s recom-
mendations (USCN LIFE SCIENCE, Houston, TX, USA).
The adsorbance was measured at 450 nm by a micro-
spectrophotometer mod. 340 ATTC (SLT Lab. Instru-
ments Salzburg, Austria). Data were expressed as pg/ml.
As reported by the manufacturer, the minimum de-
tectable dose of IL 31 is less than 5.5 pg/ml. The value
of 15.6 is referred to the lower point IL 31 standard
curve. Moreover the Lower Limit of Detection (LLD)
has been determined as follow: (Mean negative control
optical density) + 2* (StDev of negative control optical
density), as suggested by manufacturer. Our LLD was
1.9 pg/ml. In addition, to better detect IL-31 concentra-
tion in our samples, we performed a standard curve
starting from 7.8 pg/ml.
Statistical analysis
Data were expressed as medians ± SEM. Differences be-
tween two unpaired groups were analyzed by Mann–
Whitney test. The statistical analysis was performed with
SPSS for Windows (version 17.0). The level of statistical
significance was always set at P < 0.05.
Results
IL-31 serum levels in osteoporotic patients were signifi-
cantly higher compared to controls (43.12 ± 6.97 pg/ml
vs 29.58 ± 6.09 pg/ml; p = 0.049) (Fig. 1, panel a). Strati-
fying patients according to BMD values, no statistically
significant differences were found between IL-31 levels
in those affected by mild (T-score > -3) compared to
severe (T-score < -3) osteoporosis (59.17 ± 9.22 pg/ml vs
37.91 ± 10.52 pg/ml respectively; p = 0.876), as well as
between patients with mild osteoporosis and controls
(p = 0.13) and between patients with severe osteo-
porosis and controls (p = 0.059).
Considering the stratification of patients and controls
according to age (less than or equal to 65 years and
older than 65 years), in subjects under 65, the difference
between IL-31 levels in patients (n. 25) compared to
controls (n. 18) was not statistically significant (37.91 ±
6.9 pg/ml vs 32.08 ± 8.2 pg/ml; p = 0.964) (Fig. 1, panel
b), while in older subjects (over 65) IL-31 serum levels
were significantly higher in patients (n. 31) compared to
controls (n. 8) (45 ± 11.05 pg/ml vs. 17.92 ± 5.92 pg/ml;
p = 0.008) (Fig. 1, panel c).
In subjects under 65 there was no statistical difference
between IL-31 serum levels in patients with mild (n. 13)
and severe (n. 12) osteoporosis (42.08 ± 9.86 pg/ml vs.
35.02 ± 10.08 pg/ml; p = 0.87), neither between patients
with mild osteoporosis and controls (p = 0.749) and be-
tween patients with severe osteoporosis and controls
(p = 0.735).
Table 1 Clinical and anthropometric features of patients (n = 56) and controls (n = 26). Data are expressed as Mean +/- SD (min; max)
Patients Controls
Age (years) 65 +/- 9 (39; 80) 62 +/- 8 (48; 76)
Height (cm) 153 +/- 0.06 (135; 165) 152 +/- 0.05 (142; 159)
Weight (kg) 63.83 +/- 9.43 (51; 86) 64.73 +/- 11.06 (51; 83)
Body mass index (kg/m2) 26.88 +/- 4.49 (19.34; 34.78) 27.70 +/- 3.55 (22.5; 34.58)
Total hip BMD (g/cm2)* 0.701 +/- 0.07 (0.460; 0.790) 0.990 +/- 0.10 (0.890; 1.300)
Total hip T-score* −3.0 +/- 0.7 (-5.4; -2.0) −0.1 +/- 1.0 (-1.1; 3.0)
Total hip Z-score* −1.1 +/- 0.9 (-3.3; 0.2) 1.4 +/- 1.1 (-0.5; 4.0)
Calcanear QUS T-score * −3.6 +/- 0.92 (-5.5; -1.79) −0.73 +/- 1.26 (-2.3; 2.5)
ESR (mm/h)* 19.25 +/- 8.69 (6; 44) 12 +/- 7.56 (2; 27)
CRP (mg/L)* 5.75 +/- 6.60 (0.1; 41) 2.67 +/- 3.65 (0.1; 19)
BAP (μg/L) 17.68 +/- 6.57 (8.2; 30.8) 15.26 +/- 7.00 (5; 30.8)
CTX (pg/mL)* 380 +/- 246 (0.32; 900) 155 +/- 236 (5; 568))
PTH (pg/mL) 67.03 +/- 22.59 (28.6; 147) 66.04 +/- 15.20 (42.5; 88)
Legend: erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); bone alkaline phosphatase (BAP)
; C-telopeptide cross-linked collagen type 1 (CTX); parathyroid hormone (PTH)
*Statistically significant difference between patients and controls (p < 0.001)
Ginaldi et al. BMC Immunology  (2015) 16:60 Page 3 of 7
In patients over the age of 65 years with mild osteo-
porosis (n. 14), IL-31 serum levels were higher (64.17 ±
15.06 pg/ml) compared to age-matched controls (p =
0.024), as in patients with severe osteoporosis (n. 17;
44.17 ± 16.29 pg/ml) (p = 0.016), whereas no statistically
significant difference was found between IL-31 levels in
patients over 65 with mild compared to severe osteopor-
osis (p = 0.905) (Fig. 2).
We further divided all patients, according to the pres-
ence or absence of fragility fractures, into 2 groups: IL-31
serum levels did not differ significantly between fractured
(n. 15) and unfractured (n. 41) osteoporotic women
(33.75 ± 9.16 pg/ml and 51.25 ± 8.9 pg/ml; p = 0.664),
neither between controls and fractured patients
(p = 0.147), as between controls and unfractured patients
(p = 0.065). In under 65 years old patients, the levels of
IL-31 were not significantly different in fractured (n. 5)
compared to unfractured (n. 20) patients (37.9 ± 7.38
pg/ml and 37.29 ± 8.49 pg/ml respectively; p = 1). In both
fractured and unfractured patients aged less than 65 years,
IL-31 serum levels were not significantly different com-
pared to age-matched controls (p = 0.602 and p = 0.792
respectively). In over 65 patients, there was no differ-
ence between IL-31 levels in fractured (n. 10) and
unfractured (n. 21) patients (33.54 ± 13.41 pg/ml vs
59.17 ± 14.88 pg/ml; p = 0.31). IL-31 serum levels, al-
though higher in over 65 years old patients with frac-
tures compared to age-matched controls, did not reach
statistical significance (p = 0.068), whereas it was sig-
nificantly higher in over 65 unfractured patients com-
pared to age-matched controls (p = 0.008) (Fig. 3).
Data concerning clinical and anthropometric features
of healthy controls and osteoporotic patients are sum-
marized in Table 1. The differences between the two
groups were compared by means of the Student’s t test
for unpaired data and the results are shown in the table.
In particular, despite the absence of overt inflammatory
pathologies, both ESR and CRP levels were higher in
Fig. 2 IL31 serum levels in patients divided according to the severity
of osteoporosis and controls older than 65 years; lines represent medians
Fig. 3 IL31 serum levels in patients divided according to the presence
or absence of fragility fractures and controls older than 65 years; lines
represent medians
Fig. 1 IL-31 serum levels in osteoporotic patients and controls according to age. a: IL31 serum levels in all patients and controls; lines represent
medians. b: IL31 serum levels in patients and controls less than or equal to 65 years; lines represent medians. c: IL31 serum levels in patients and
controls older than 65 years; lines represent medians
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patients compared to controls (19.25 + 8.69 mm/h vs 12
+ 7.56 mm/h and 5.75 + 6.6 mg/L vs 2.67 + 3.65 mg/L re-
spectively; p < 0.001). Although the osteoporosis group
could appear older than controls, the age difference was
not statistically significant (p = 0.108). Also the BMI of
the patients was substantially comparable to that of the
controls (26.88 + 4.49 vs 27.70 + 3.33; p = 0.415), exclud-
ing any bias linked to the influence of this anthropomet-
ric parameter on the T-score. Besides the values of T-
score (-3.0 + 0.7 vs -0.1 + 1; p < 0.001), also BMD values
expressed as Z-scores (-1.1 + 0.9 vs 1.4 + 1.1; p < 0.001)
and g / cm2 (0.701 + 0.07 vs 0.990 + 0.10; p < 0.001) are
significantly higher in osteoporotic patients than controls.
Discussion
The major part of recent studies seeking to understand
how the immune system impacts and regulates bone re-
modelling in physiological and pathological conditions
through the immunoskeletal interface, have led to a new
concept of osteoporosis as a sort of chronic immune
mediated disease [1, 2]. Aging and estrogen deficiency
are probably the two most important risk factors in de-
veloping osteoporosis, although decreased bone mineral
density could be related to diverse pathological condi-
tions [4, 6], and in each of these, the influence of very
basic determining factors are prevalent rather than
others. A possible correlation between plasma levels of
certain cytokines and development of osteoporosis has
been reported [13, 14]. Significant examples are the ele-
vated production of IFN-γ, IL-6 and IL-17 consequent to
an estrogen deficit in menopausal osteoporosis [12, 36]
or the action of TNF-α in secondary osteoporosis due to
rheumatoid arthritis [14].
In this study, we have demonstrated for the first time
an increase of IL-31 serum levels in postmenopausal
women with decreased bone mineral density, discovering
that there seems to be a correlation between this cyto-
kine and osteoporosis. Serum IL-31 levels did not reflect
the severity of osteoporosis, as assessed by BMD values
and/or the presence of fractures. The fact that levels of
this cytokine don’t correlate neither with the severity of
osteoporosis nor with the presence of fractures, appears
to exclude the possibility that its increased expression is
linked to the role of this cytokine in the progression of
the disease. However, the loss of statistical significance
between individual subgroups could likely be attributed
to the low number of individuals per group and the dis-
persion of the values of Il-31. The extension of the study
to a larger number of patients will better define the in-
volvement of IL-31 in the pathogenesis of osteoporosis.
Moreover, our data clearly showed a relationship be-
tween IL-31 expression and osteoporosis in aging, as
reflected by the higher levels of this cytokine in aged
patients. These findings open the door to a better under-
standing of the multiple functions of IL-31 in aging as
well as in age-related diseases, and provide a new link
between bone resorption and IL-31 during aging, sug-
gesting a peculiar role of IL-31 in senile osteoporosis.
IL-31 and its receptors are involved in the regulation
of hematopoietic progenitor cell homeostasis and in par-
ticular are implicated in the homeostasis of myeloid
progenitor cells [17, 21], which are also the common
precursors of osteoclasts, the cells specialized in bone
resorption [1, 37]. In addition, this cytokine is capable of
inducing monocyte activation [17, 38]. It has been docu-
mented that IL-31 increases the transcription of proin-
flammatory genes and induces pro-inflammatory effects
in activated human monocytes and macrophages [26].
A variety of cytokines and transcription factors are
reported to be involved in the development of osteopor-
osis, and some of them are regulated by IL-31 [17, 19,
20, 26, 29, 39]. Engagement of the receptor complex re-
sults in activation of Janus kinase (JAK) tyrosine kinases
and subsequently of different signalling molecules, in-
cluding different signal transducers and activators of
transcription (STAT) factors, Akt, NF-κB [17, 18, 29], as
well as the MAPK [29, 30] and PI3K signalling pathways
[40]. These pathways are involved in bone remodelling
as well as in inflammation [2, 4]. In particular, STAT-1
and STAT-3 proteins are important transcription factors
mediating the intracellular events leading to osteoclastic
proliferation and activation [41].
Several studies showed that IL-31 stimulated secretion
of proinflammatory osteoclastogenic cytokines, chemo-
kines and matrix metalloproteinases [17, 19, 26, 39], all
of which are implicated in differentiation, recruitment
and function of osteoclasts and are therefore key media-
tors of bone remodelling during aging [7, 13, 37, 42]. In
particular, previous findings have revealed that IL-31
could significantly induce the release of the proinflam-
matory and osteoclastogenic cytokines IL-1β, IL-6 and
chemokines CXCL1, CXCL8, CCL2 and CCL18 from
various cell types [17]. These data indicate that IL-31
may function as a proinflammatory cytokine involved in
recruitment of osteoclast precursors and in immune me-
diated bone resorption. The effects of IL-31 are in some
way comparable to IL-17A: these two cytokines show
additive effects in stimulating the secretion of proinflam-
matory cytokines and chemokines with bone resorbing
capacity [17, 20].
Moreover, proinflammatory cytokines increase, in turn,
the expression of IL31 and its receptor complex. The
strongest upregulation of IL31, IL31Rα, and OSMR gene
expression has been shown after stimulation with IFN‐γ,
IL-1β and TNF-α [4, 17, 20, 26]. It has been demon-
strated that also reactive oxygen species, which are in-
creased with aging, stimulate the expression of IL-31 in
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T cells, monocytes and monocyte-derived dendritic cells,
inducing inflammatory responses, and this could po-
tentiate age-related bone resorption [39, 43].
The higher levels of CTX and the increase of inflam-
matory markers in patients compared to controls seem
to confirm the presence of a condition of low-grade in-
flammation and increased bone resorption in osteopor-
osis. In previous studies, in addition to the increase of
inflammation markers, we also documented increased
serum levels of well-known proresorptive inflammatory
cytokines, such as IL-6 and TNF-α, in osteoporotic pa-
tients compared to healthy subjects [44].
Interestingly, IL-17 and senescent memory T cells are
the main mediators of bone loss during senescence and
inflammaging, that is the progressive establishing of a
chronic inflammatory state linked to the continuous
long exposure to antigens and ROS during aging [7, 44].
The immunosenescence is characterized by accumula-
tion of memory T cells and exhaustion of naive T cells,
as well as by activation of effector inflammatory cells,
macrophages and Th17 lymphocytes [44]. Aged osteo-
porotic subjects displayed significantly higher IL-31
levels with respect to both young and old controls.
It has been proposed that osteoporosis represents a
Th1 and Th17 mediated bone inflammation, whereas
Th2 cytokines, such as IL-4, display an antiosteoporotic
protective function [1, 2, 4, 13–16, 19, 22, 37]. Based on
the nature of its main producing cells, IL-31 is consid-
ered a Th2 cytokine, its involvement having also been
predominantly described firstly in respiratory hypersen-
sitivity and in atopic dermatitis [18, 31]. However IL-31
RNA expression has been reported also in Th1 cells,
though higher levels of IL-31 mRNA were observed in
Th2 cells [20]. Moreover, its prevalent involvement in
the chronic state of atopic dermatitis, were Th1 weighted
inflammation is involved, has been documented [28].
Therefore, IL-31 may rather play a role unique to osteo-
porosis, which represent a chronic condition where Th1
inflammation plays a more dominant role. In addition, in
vitro observations indicate that IL-31 can positively and
negatively affect Th1 and Th17 differentiation in an APC-
free system [17]. These data suggest a potential function
for IL-31 in regulating immune responses and inflamma-
tion through modulating antigen-presenting cells or more
directly T cell themselves and implicate IL-31/IL-31R
signalling as a negative regulatory pathway that specif-
ically could limit type 2 inflammation, which is mainly
protecting against osteoporosis [45].
Therefore, this study reveals the relationship between
IL-31 expression and osteoporosis. However, the precise
signal transduction mechanism mediating the effects of
IL-31 and its interaction with other cytokines and tran-
scription factors implicated in bone remodelling have
to be elucidated. It is likely that additional signals from
different cell types modulate IL-31 activity in aged osteo-
porotic patients. The demonstration of the strong increase
of IL-31 in aged osteoporotic subjects may contribute to a
better understanding of the mechanisms at the basis of
the capacity of the immune system of aged individuals to
mount osteoclastogenic immune reactions through pecu-
liar inflammatory responses that may be crucial in senile
osteoporosis.
In conclusion, this is the first report on a relationship
between IL-31 and bone resorption in aging. Moreover,
IL-31 increase that we found in aged osteoporotic pa-
tients, probably related to the increased release of this
cytokine by senescence inflammatory immune cells,
might therefore contribute to the development of a con-
dition of full-blown osteoporosis.
Conclusion
The increased IL-31 serum levels in aged osteoporotic
patients suggests a relationship between bone resorp-
tion and overexpression of this cytokine. Elevated IL-31
expression could enhance bone resorption through the
induction of chemokines and proinflammatory osteo-
clastogenic cytokines, which subsequently lead to the
recruitment of osteoclast precursors from the bone
marrow, their differentiation and activation. Our results
suggest that an important role is played by IL-31 in se-
nile osteoporosis. However, how IL-31 acts in concert
with known mediators of bone remodelling, remains to be
determined. A precise understanding of the involvement
of this newly discovered cytokine in the immunopathology
of bone resorption is critical to provide more effective
strategies for senile osteoporosis treatment.
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